Key Points
- Insider sale: Tempus EVP Andrew Polovin sold 10,949 shares on Feb. 20 at an average of $60.31 for about $660,334, reducing his stake by 7.94% to 126,918 shares; he also sold 8,143 shares on Feb. 19 and 12,874 shares on Nov. 24.
- Stock context and catalysts: TEM opened at $58.37 (down ~2.7%) with a ~$10.4B market cap — recent product catalysts (a pan‑cancer HRD‑RNA tool and broader AI rollout) and Mizuho's bullish initiation contrast with negative GAAP profitability, elevated debt/volatility, and a consensus analyst rating of "Hold" (PT $85.92).
- Institutional interest: Invesco boosted its Q4 stake by 21.5% to 371,674 shares and overall hedge funds/institutions own about 24.22% of the company, indicating rising institutional positioning despite mixed sentiment.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CAO Ryan Bartolucci sold 2,902 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $171,363.10. Following the completion of the sale, the chief accounting officer owned 41,159 shares of the company's stock, valued at approximately $2,430,438.95. The trade was a 6.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Tempus AI Stock Down 2.7%
Shares of TEM stock opened at $58.37 on Friday. The stock's 50 day simple moving average is $62.35 and its 200 day simple moving average is $73.39. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28. Tempus AI, Inc. has a twelve month low of $36.22 and a twelve month high of $104.32. The company has a market capitalization of $10.38 billion, a price-to-earnings ratio of -49.05 and a beta of 5.22.
Analysts Set New Price Targets
TEM has been the topic of a number of research analyst reports. JPMorgan Chase & Co. decreased their price objective on shares of Tempus AI from $85.00 to $80.00 and set a "neutral" rating on the stock in a report on Monday, December 15th. Robert W. Baird began coverage on shares of Tempus AI in a research report on Tuesday. They issued an "outperform" rating and a $59.00 price target on the stock. Morgan Stanley lifted their target price on Tempus AI from $80.00 to $85.00 and gave the stock an "overweight" rating in a report on Monday, December 1st. Canaccord Genuity Group cut their target price on Tempus AI from $95.00 to $80.00 and set a "buy" rating on the stock in a research note on Monday, December 22nd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Tempus AI in a research report on Thursday, January 22nd. Eight equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Tempus AI has a consensus rating of "Hold" and an average target price of $85.92.
Get Our Latest Stock Report on TEM
More Tempus AI News
Here are the key news stories impacting Tempus AI this week:
- Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
- Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI's Expansion Across MedTech
- Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
- Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
- Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
- Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
- Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus
Institutional Investors Weigh In On Tempus AI
Several large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its stake in Tempus AI by 201.2% in the 1st quarter. Royal Bank of Canada now owns 25,988 shares of the company's stock worth $1,253,000 after buying an additional 17,359 shares in the last quarter. Rhumbline Advisers bought a new position in shares of Tempus AI during the 1st quarter valued at about $116,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Tempus AI during the 2nd quarter valued at about $307,000. Atria Wealth Solutions Inc. bought a new stake in Tempus AI in the 2nd quarter worth approximately $214,000. Finally, Allianz Asset Management GmbH boosted its stake in shares of Tempus AI by 52.9% in the 2nd quarter. Allianz Asset Management GmbH now owns 10,400 shares of the company's stock valued at $661,000 after purchasing an additional 3,600 shares in the last quarter. Institutional investors own 24.22% of the company's stock.
Tempus AI Company Profile
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
